Community oncology practices need to come together as much as possible in order to respond to changes in the market, have a common voice, and to share best practices and learn from each other, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Community oncology practices need to come together as much as possible in order to respond to changes in the market, have a common voice, and to share best practices and learn from each other, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Transcript
What were the main takeaways from the Quality Cancer Care Alliance (QCCA) Winter Summit from the perspective of practice management?
The main takeaway that I walked away from the QCCA summit with is that this oncology world is getting more and more challenging. There’s so many things going on that we really need to work together as community oncology practices as much as possible in order to be able to respond to all the changes in the market, have a common voice about input we want to have in the market, and to also be able to benchmark with each other to have best practices and learn from each other.
There’s so many different things going on in so many different parts of the country, and a lot of times as a community oncology practice you feel sort of isolated, and what the QCCA program really did was give you a sense that there are a lot of other folks in the same boat with you and if we can all get on the same page and learn from each other and have a voice collectively we can make a difference.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More